REFERENCES
- Eklund B, Carlson L A. Central and peripheral circulatory effects and metabolic effects of different prostacnglandins given I.V. to man. Prostaglandins 1980; 20: 333–347
- Robertson R P. Eicosanoids and human disease. Harrison’s Principles of Internal Medicine, J D Wilson, E Braunwald, K J Isselbacher, R G Petersdorf, J B Martin, A S Fauci, R K Root. 12th ed., McGraw Hill, New York 1991; 397–401
- Olin B R. Drug Facts and Comparisons. Facts and Comparisons, St. Louis 1991
- Reynolds J EF. Martindale: The extra pharmacopoeia. Pharmaceutical Press, London 1993
- Levine L A, Kranc D M. Evaluation of carboprost tromethamine in the treatment of cyclophosphamide- induced hemorrhagic cystitis. Cancer 1990; 66: 242–245
- Marmo E, Somma A, Ottavo R, Vairo G, Spaziante G, Dimezza F, Paone G. Effects of prostacyclin, 6-keto-PGF1 alpha and 15[s]15-methyl-PGF2 alpha on platelet aggregation in vitro. J. Med. 1981; 12: 97–108
- Cooley D M, Glosten B, Roberts J R, Eppes P D, Barnes R B. Bronchospasm after intramuscular 15-methyl prostaglandin F2a and endotracheal intubation in a nonasthmatic patient. Anesth Analg 1991; 73: 87–89
- Hankins G D, Berryman G K, Scott R T, Hood D. Maternal arterial desaturation with 15-methyl prostaglandin F2 alpha for uterine atony. Obstet Gynecol 1988; 73: 367–370
- Tripathy S N. Uterine rupture following intramuscular injection of carboprost in midtrimester pregnancy termination. J Ind Med Assoc 1985; 83: 328
- Drugdex Editorial Staff: Carboprost (Drug Evaluations Monograph). Drugdex System. Micromedex, Inc., Englewood, Colorado, 397–401, expires 11/30/98
- Martin C. Upjohn, personal communication. March, 181996